List of Digital Health/Medicine Companies with Phase 4 Active Clinical Trial - 16

Astellas Pharma US, Inc. is an affiliate of Tokyo-based Astellas Pharma Inc., a top 20 global pharmaceutical research company. Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the Americas and around the world. All content developed by Astellas Pharma US, Inc. and intended for U.S. audiences.

Driven by innovative science and our entrepreneurial culture, we are focused on the delivery of life-changing medicines that are fuelling growth and contributing value to patients and society.

Cadence Neuroscience is developing a fundamentally new approach to neuromodulation, starting with a therapy to treate severe epilepsy.

CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions. NASDAQ:CDNA About AlloSure® AlloSure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. AlloSure is a clinical-grade, proprietary Next-Generation Sequencing (NGS) based test to detect donor-derived cell-free DNA (dd-cfDNA) in order to identify organ injury in kidney transplant recipients. AlloSure is analytically validated as a sensitive, specific, and precise measurement of dd-cfDNA. AlloSure detects active rejection (acute active ABMR, chronic active ABMR, or TCMR) with high accuracy, outperforms serum creatinine in kidney transplant recipients, and is highly sensitive in distinguishing ABMR from no ABMR. AlloSure is performed in the CareDx CLIA-certified laboratory. http://www.allosure.com/ About AlloMap® AlloMap Molecular Expression Testing is a non-invasive blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the CareDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients. http://www.allomap.com/

Dong-A ST is a company established in March 2013 following the restructuring of the former Dong-A Pharmaceutical into a holding company. Our company focuses on the development and sale of specialized pharmaceuticals (ETC) and is dedicated to the philosophy of "Our company's social contribution is in new drug development." With state-of-the-art research facilities such as the Yongin Research Center established in 1977 and the completion of the Songdo Research Center in 2021, Dong-A ST has been striving for innovative global new drug development with excellent research and development capabilities. For many years, by consistently investing more than 10% of its revenue in R&D, we have successfully developed multiple proprietary novel drugs, including Stillen, Zydena, Motilitone, Sivextro, and Suganon/Sugamet.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Epitel is a digital health company modernizing brain health solutions to improve seizure monitoring and detection.

Huma is a global healthcare AI company on a mission to accelerate the adoption of digital solutions in care and research. Huma's technology has powered over 3,000 hospitals and clinics, with 500+ unique deployments across 70+ countries. The software has been used to engage and screen over 35 million individuals, with 1.8 million active users across its various products. The company is renowned for its role in major national healthcare projects worldwide, from the US and the UK to Germany, Greece, and Saudi Arabia, as well as working with most large pharma companies and CROs. The Huma Cloud Platform offers a technology infrastructure built on strong regulatory foundations to launch digital solutions for healthcare and research. Huma has achieved FDA 510(k) Class II, EU/MDR Class IIb, and Saudi FDA Class C regulatory clearance for its disease-agnostic flagship product, enabling rapid, code-free configuration with the ability to host AI/ML models.

ICON works to accelerate the development of live-saving drugs and devices by providing a wide range of consulting, development, and commercialization services.

Innodem Neurosciences is committed to improving the effectiveness and quality of life and care of patients with neurological problems. Innodem works with the pharmaceutical industry, leading medical professionals, and artificial intelligence experts to develop and promote Eye Movement Biomarkers (EMBs) & Gaze Mapping Biomarkers (GMBs) as important clinical assessment tools in the field of neurology. It is building a series of disease-specific tests embodied in an intuitive App that captures EMB & GMB data. The vision is that over time, while leveraging the latest advances in machine and deep learning, this EMB/GMB platform will assist users to accurately diagnose and monitor neurological disorders affecting eye-movements or cognition such as multiple sclerosis, Alzheirmer's, Parkinson's or related disorders, Frontotemporal dementia, Cancer-related cognitive impairment (Chemo Brain) and many others.

At Kestra, we stand for patients at-risk and the people who care for them. Together we work to protect, support, and empower them with wearable technologies, tools, and better answers as they navigate life's most challenging medical events. Cardiovascular disease is the number one cause of death globally. We're taking a fresh approach to cardiac monitoring and delivery of definitive therapy with wearable products and applications. We aim to make the entire recovery process easier for patients by bringing comfort and assurance to them—along with advanced clinical insights and tools to their medical care teams. Kestra is a privately held, Bain Capital portfolio company, headquartered in Kirkland, Washington USA. Visit us at www.kestramedical.com

Koneksa is a leading patient-centric digital biomarker company for the pharmaceutical and biotechnology industries that develops end-to-end solutions for remotely collected clinical data. Koneksa supports agile decision-making in drug development and market strategy. By delivering integrated solutions for efficient trial designs that produce more meaningful data, Koneksa aims to revolutionize effect detection in clinical research.

Premier Research, a global clinical research, product development, and consulting company, is dedicated to helping innovators transform life-changing ideas and breakthrough science into new medical treatments. We offer strategic solutions across the entire development lifecycle, from pre-clinical through commercialization, specializing in smart study design and full-service clinical trial management. Leveraging technology and therapeutic expertise, we deliver clean, conclusive data with a focus on reducing development timelines, securing access to the right patients, and effectively navigating global regulations to ensure submission-ready results. As an organization that puts patients first, we pride ourselves on helping customers answer the unmet needs of patients across a broad range of medical conditions. Are you ready to make a real difference and help us transform this exciting industry? Follow our company page for more information about us and the work we do, and check out our current openings for your next career move!

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation

Sonde Health is a health technology company with a voice-enabled symptom detection and monitoring platform for chronic and mental health conditions. Our products are based on patented and proprietary, best-in-class technology developed by amazing people with advanced audio signal processing, speech science and machine learning backgrounds. We analyze over 4,000 vocal features that reflect changes in your voice caused by the changing physiology of your body due to symptoms of disease. Sonde's platform is designed with people's privacy in mind, and work on most smartphones people already own, preventing you from having to wear something new or add anything to your busy life.

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at stryker.com and careers.stryker.com. Facts: ● 2023 Sales: $20.5 billion ● Industry: Medical Instruments & Supplies ● Employees: 52,000 worldwide ● 40 years of sales growth leading up to 2020 ● 44+ Manufacturing and R&D Locations Worldwide ● $1.4 billion spent on research and development in 2023 ● ~12,900 patents owned globally in 2023 ● Products sold in ~75 countries ● Fortune 500 Company ● 7 consecutive years as one of Fortune's World's Best Workplaces Stryker’s social media community guidelines: https://www.stryker.com/content/m/legal/social-media-community-guidelines/en/index.html Notice Regarding Employee Conduct on Facebook/LinkedIn Meta/LinkedIn does not permit employers to verify or validate “employees” in the (META: “Works at” LinkedIn: “Experience”) section of users’ profiles. Please be aware that the views expressed by individuals on their personal accounts and do not necessarily represent the views of our company. If you encounter any issues with a person claiming to be our employee, we recommend using the “Report Profile” feature. If you’d like to report concerns to our Ethics Hotline, you may do so at: https://app.convercent.com/en-us/LandingPage/b6bb4e84-9fcb-ea11-a974-000d3ab9f296